menu
    • menu
    [{"orgOrder":0,"company":"Gylden Pharma","sponsor":"Vickers Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Series A Financing","leadProduct":"Set-point vaccines","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Gylden Pharma","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"","sponsorNew":"Gylden Pharma \/ Vickers Venture Partners","highestDevelopmentStatusID":"6","companyTruncated":"Gylden Pharma \/ Vickers Venture Partners"},{"orgOrder":0,"company":"Gylden Pharma","sponsor":"Gylden Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"Set-point vaccines","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Gylden Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Gylden Pharma \/ Emergex","highestDevelopmentStatusID":"1","companyTruncated":"Gylden Pharma \/ Emergex"},{"orgOrder":0,"company":"Gylden Pharma","sponsor":"Institute of Technology on Immunobiologicals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"Yellow fever vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Gylden Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Gylden Pharma \/ Institute of Technology on Immunobiologicals","highestDevelopmentStatusID":"4","companyTruncated":"Gylden Pharma \/ Institute of Technology on Immunobiologicals"},{"orgOrder":0,"company":"Gylden Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"PepGNP-Dengue","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Gylden Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Gylden Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Gylden Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Gylden Pharma","sponsor":"NanoPass Technologies","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"LD PepGNP-SARSCoV2","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Gylden Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Gylden Pharma \/ Emergex","highestDevelopmentStatusID":"6","companyTruncated":"Gylden Pharma \/ Emergex"},{"orgOrder":0,"company":"Gylden Pharma","sponsor":"Department of Health and Social Care","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2022","type":"Funding","leadProduct":"Synthetic T-cell Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Gylden Pharma","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Microneedle Patch","sponsorNew":"Gylden Pharma \/ Department of Health and Social Care","highestDevelopmentStatusID":"2","companyTruncated":"Gylden Pharma \/ Department of Health and Social Care"},{"orgOrder":0,"company":"Gylden Pharma","sponsor":"ATCC","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2022","type":"Agreement","leadProduct":"Yellow Fever Booster Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Gylden Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Gylden Pharma \/ ATCC","highestDevelopmentStatusID":"4","companyTruncated":"Gylden Pharma \/ ATCC"},{"orgOrder":0,"company":"Gylden Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"Tularemia Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Gylden Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Gylden Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Gylden Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Gylden Pharma","sponsor":"Molecular Biology Institute of Parana","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2022","type":"Collaboration","leadProduct":"CD8+ T Cell Adaptive Vaccine","moa":"CD8+ T-Cell","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Gylden Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Gylden Pharma \/ Molecular Biology Institute of Parana","highestDevelopmentStatusID":"6","companyTruncated":"Gylden Pharma \/ Molecular Biology Institute of Parana"},{"orgOrder":0,"company":"Gylden Pharma","sponsor":"Zosano Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Acquisition","leadProduct":"CD8+ T-cell Adaptive Vaccine","moa":"CD8+","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Gylden Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Microneedle Patch","sponsorNew":"Gylden Pharma \/ Emergex Vaccines Holding","highestDevelopmentStatusID":"1","companyTruncated":"Gylden Pharma \/ Emergex Vaccines Holding"},{"orgOrder":0,"company":"Gylden Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"T Cell Adaptive Chikungunya Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Gylden Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Gylden Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Gylden Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Gylden Pharma","sponsor":"University of Lausanne Hospitals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"CD8+ T Cell Adaptive Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Gylden Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Gylden Pharma \/ University of Lausanne Hospitals","highestDevelopmentStatusID":"6","companyTruncated":"Gylden Pharma \/ University of Lausanne Hospitals"},{"orgOrder":0,"company":"Gylden Pharma","sponsor":"IBMP","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2023","type":"Collaboration","leadProduct":"EMX-001","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Gylden Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Gylden Pharma \/ IBMP","highestDevelopmentStatusID":"6","companyTruncated":"Gylden Pharma \/ IBMP"},{"orgOrder":0,"company":"Gylden Pharma","sponsor":"Vaccine Industrial Company","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2023","type":"Agreement","leadProduct":"CD8+ T-cell Adaptive Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Gylden Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gylden Pharma \/ Vaccine Industrial Company","highestDevelopmentStatusID":"6","companyTruncated":"Gylden Pharma \/ Vaccine Industrial Company"},{"orgOrder":0,"company":"Gylden Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2024","type":"Not Applicable","leadProduct":"PepGNP-COVID19 Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Gylden Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gylden Pharma \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Gylden Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Gylden Pharma","sponsor":"DEKA Research & Development","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Collaboration","leadProduct":"DengueTcP","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Gylden Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gylden Pharma \/ Emergex Vaccines Holding","highestDevelopmentStatusID":"6","companyTruncated":"Gylden Pharma \/ Emergex Vaccines Holding"},{"orgOrder":0,"company":"Gylden Pharma","sponsor":"Zosano Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"Zolmitriptan","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Gylden Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Microneedle Patch","sponsorNew":"Gylden Pharma \/ Emergex Vaccines Holding","highestDevelopmentStatusID":"10","companyTruncated":"Gylden Pharma \/ Emergex Vaccines Holding"}]

    Find Clinical Drug Pipeline Developments & Deals by Gylden Pharma

    Menu

    Gylden Pharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Gylden Pharma

                            United Kingdom arrow
                            BioAsia
                            Not Confirmed

                            Gylden Pharma

                            United Kingdom arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DengueTcP

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Recipient : DEKA Research & Development

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Emergex Partners with DEKA for Assessment of Immunotherapeutic Candidates with Applicator

                            Details : The collaboration aims to assess the compatibility of Emergex’s immunotherapeutic candidates, including EMX-001 (dengueTcP) with the DEKA Intradermal Therapeutic Applicator.

                            Product Name : EMX-001

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            January 16, 2024

                            Lead Product(s) : DengueTcP

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Recipient : DEKA Research & Development

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Gylden Pharma

                            United Kingdom arrow
                            BioAsia
                            Not Confirmed

                            Gylden Pharma

                            United Kingdom arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PepGNP-COVID19 Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Emergex Gets Authorization to Start Phase I-II Trial of CoronaTcP in the Philippines

                            Details : CoronaTcP (PepGNP-COVID19 Vaccine) designed to be broadly effective against disease caused by Betacoronaviruses, including SARS-CoV-1, as well as known and emerging variants of SARS-CoV-2.

                            Product Name : CoronaTcP

                            Product Type : Vaccine

                            Upfront Cash : Not Applicable

                            January 03, 2024

                            Lead Product(s) : PepGNP-COVID19 Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Gylden Pharma

                            United Kingdom arrow
                            BioAsia
                            Not Confirmed

                            Gylden Pharma

                            United Kingdom arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Zolmitriptan

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Recipient : Zosano Pharma

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Successful Transfer of New Drug Application (NDA), Acknowledged by U.S. FDA, from Former Zosano Pharma to Emer...

                            Details : The assets acquired include Zosano’s proprietary microneedle array patch (MAP) intradermal drug delivery system, intended for the epidermal delivery of M207 (zolmitriptan) for the treatment of migraine attacks in adults.

                            Product Name : M207

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            December 18, 2023

                            Lead Product(s) : Zolmitriptan

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Recipient : Zosano Pharma

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Gylden Pharma

                            United Kingdom arrow
                            BioAsia
                            Not Confirmed

                            Gylden Pharma

                            United Kingdom arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CD8+ T-cell Adaptive Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Vaccine Industrial Company

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Emergex and Saudi Arabia’s Vaccine Industrial Company (VIC) have Signed MoU to Advance First-of-its-Kind Inf...

                            Details : The agreement aims for advancing Emergex’s novel T cell-priming immune set-point candidates against designated infectious diseases, including CoronaTcP, a multi-target T cell-priming set-point product, for Betacoronaviruses and DengueTcP, a candidate a...

                            Product Name : naNO-Dengue

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            October 05, 2023

                            Lead Product(s) : CD8+ T-cell Adaptive Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Vaccine Industrial Company

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Gylden Pharma

                            United Kingdom arrow
                            BioAsia
                            Not Confirmed

                            Gylden Pharma

                            United Kingdom arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EMX-001

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : IBMP

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Emergex and Brazil's IBMP Announce Clinical Development Collaboration for T Cell-Priming Immune Set-Point Cand...

                            Details : Under the collaboration, Emergex and IBMP have agreed to co-fund Phase II and Phase III studies in Brazil of Emergex’s T cell-priming set-point candidates for Dengue Fever and Betacoronavirus, known respectively as DengueTcPâ„¢ (EMX-001) and CoronaTcPâ...

                            Product Name : DengueTcP

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            June 20, 2023

                            Lead Product(s) : EMX-001

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : IBMP

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Gylden Pharma

                            United Kingdom arrow
                            BioAsia
                            Not Confirmed

                            Gylden Pharma

                            United Kingdom arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CD8+ T Cell Adaptive Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : University of Lausanne Hospitals

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Emergex Announces Positive Phase I Trial Data for DengueTcPâ„¢, Its Novel T Cell-Priming Immune Set-Point Cand...

                            Details : DengueTcP (CD8+ T Cell Adaptive Vaccine) immune set-point product to treat dengue, is designed to elicit a specific CD8+ T cell immune response without affecting the humoral response.

                            Product Name : DengueTcP

                            Product Type : Vaccine

                            Upfront Cash : Not Applicable

                            June 06, 2023

                            Lead Product(s) : CD8+ T Cell Adaptive Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : University of Lausanne Hospitals

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Gylden Pharma

                            United Kingdom arrow
                            BioAsia
                            Not Confirmed

                            Gylden Pharma

                            United Kingdom arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : T Cell Adaptive Chikungunya Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Emergex Generates Chikungunya Ligandome, a Milestone in the Development of its T cell Adaptive Vaccine

                            Details : The ligandome library which contains viral and self MHC class I peptides has been established successfully by using the Emergex proprietary vaccine development platform, which provides a rational basis for CD8+ T cell vaccine development.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Not Applicable

                            November 28, 2022

                            Lead Product(s) : T Cell Adaptive Chikungunya Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Gylden Pharma

                            United Kingdom arrow
                            BioAsia
                            Not Confirmed

                            Gylden Pharma

                            United Kingdom arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CD8+ T-cell Adaptive Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Recipient : Zosano Pharma

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Emergex Acquires Intradermal and Patch Drug Delivery Technology with Its Manufacturing Equipment from Zosano P...

                            Details : The MAP technology developed by Zosano is an exceptional strategic fit that complements our CD8+ T cell Adaptive Vaccine platform and intend to develop the MAP technology acquired from Zosano for delivery of vaccines.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            October 12, 2022

                            Lead Product(s) : CD8+ T-cell Adaptive Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Recipient : Zosano Pharma

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Gylden Pharma

                            United Kingdom arrow
                            BioAsia
                            Not Confirmed

                            Gylden Pharma

                            United Kingdom arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CD8+ T Cell Adaptive Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Molecular Biology Institute of Parana

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Emergex Vaccines Signs Heads of Terms for A Collaboration with Molecular Biology Institute of Parana (IBMP) in...

                            Details : The agreement initially focuses on Emergex’s Dengue vaccine candidate and also includes the shared development and commercialisation of COVID-19 and Chikungunya vaccine candidates.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            July 01, 2022

                            Lead Product(s) : CD8+ T Cell Adaptive Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Molecular Biology Institute of Parana

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Gylden Pharma

                            United Kingdom arrow
                            BioAsia
                            Not Confirmed

                            Gylden Pharma

                            United Kingdom arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tularemia Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Emergex Advances Vaccine Candidate for Tularemia, Highlighting the Potential of T cell Priming Vaccines in Nat...

                            Details : Emergex intends to use its previously determined repertoire of Class I peptides to generate a CD8+ T cell Adaptive Vaccine as medical countermeasure for better preparedness against naturally occurring, accidental, or deliberate exposures to the bacterium...

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Not Applicable

                            April 14, 2022

                            Lead Product(s) : Tularemia Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth